AI Medical Service Inc. (AIM), a medical startup specialising in the development of diagnostic endoscopic AI, signed a joint research agreement last month with Mahidol University in Thailand and has begun research activities. AIM is the first Japanese company to sign a joint research agreement with Mahidol in the field of endoscopic AI, and Mahidol is the first Thai institute that AIM has collaborated with thus far.

AIM received manufacturing and marketing approval from Japan’s Minister of Health for an AI-equipped endoscopic imaging diagnosis support system in December 2023. The endoscopic AI detects lesion candidates for biopsy or other additional exam based on gross features during endoscopic examination, and kicked off sales in March 2024. Furthermore, AIM has also completed regulatory review and device registration for the same basic product in Singapore in February 2024.

AIM is aiming to expand its products reach beyond Japan to clinical sites worldwide. Collaboration with Mahidol will facilitate joint research designed to test the applicability of Japanese endoscopic AI in Thailand.